Development of biosimilars in an era of oncologic drug shortages

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 3247-3255

  Li, Edward ^a   Subramanian, Janakiraman ^b   Anderson, Scott ^c   Thomas, Dolca ^c   McKinley, Jason ^c   Jacobs, Ira A ^c  

^a UNIVERSITY OF NEW ENGLAND   (United States)

^b Hanna Cancer Associates   (United States)

^c PFIZER INC   (United States)

Author keywords

Biologics; Cancer; Monoclonal antibody; Rituximab; Safety; Trastuzumab

Indexed keywords

ABP 980; ANTINEOPLASTIC AGENT; BCD 020; BCD 021; BCD 022; BEVACIZUMAB; BIOSIMILAR AGENT; BLEOMYCIN; CETUXIMAB; CT P 6; CYTARABINE; DOXORUBICIN; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; GENERIC DRUG; GP 2013; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; PF 05280014; PF 05280586; PF 06439535; RITUXIMAB; RTXM 83; TRASTUZUMAB; UNCLASSIFIED DRUG;

CANCER PATIENT; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG CHOICE; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG INDICATION; DRUG MANUFACTURE; DRUG SAFETY; DRUG SHORTAGE; DRUG THERAPY; EUROPEAN MEDICINES AGENCY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HOSPITAL; HUMAN; MEDICAL ETHICS; ONCOLOGIST; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT SAFETY; REVIEW; RHEUMATOID ARTHRITIS; THERAPY DELAY; DRUG COST; DRUG INDUSTRY; ECONOMICS; FORECASTING; HEALTH CARE DELIVERY; NEOPLASMS; RISK ASSESSMENT; RISK FACTOR; SUPPLY AND DISTRIBUTION; TRENDS;

ANTINEOPLASTIC AGENTS; BIOSIMILAR PHARMACEUTICALS; DELIVERY OF HEALTH CARE; DRUG COSTS; DRUG INDUSTRY; FORECASTING; HUMANS; NEOPLASMS; PATIENT SAFETY; RISK ASSESSMENT; RISK FACTORS;

EID: 84933073892     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S75219     Document Type: Review

References (65)

1. Gogineni K, Shuman KL, Emanuel EJ. Survey of oncologists about shortages of cancer drugs. N Engl J Med. 2013;369(25):2463-2464.
2. US Food and Drug Administration. Washington, DC: US Food and Drug Administration; 2014. MAPP 6003.1: Manual of Policies and Procedures. Available from: http://www.fda.gov/downloads/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/manualofpoliciesprocedures/ucm079936.pdf. Accessed September 15, 2014.
3. American Society of Health Systems Pharmacists [webpage on the internet]. Drug shortages: current drugs. Available from: www.ashp.org/menu/DrugShortages/CurrentShortages. Accessed September 15, 2014.
4. US Food and Drug Administration. Washington, DC: US Food and Drug Administration; 2011. A Review of FDA's Approach to Medical Product Shortages. Available from: http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UCM277755.pdf. Accessed September 15, 2014.
5. McKeever AE, Bloch JR, Bratic A. Drug shortages and the burden of access to care: a critical issue affecting patients with cancer. Clin J Oncol Nurs. 2013;17(5):490-495.
6. Elzawawy AM, Kerr DJ. Variation in the availability of cancer drug generics in the United States of America. Ann Oncol. 2013;24(Suppl 5):v17-v22.
7. American Hospital Association. Washington, DC: American Hospital Association; 2011. AHA Survey on Drug Shortages. Available from: http://www.aha.org/content/11/drugshortagesurvey.pdf. Accessed September 15, 2014.
8. Kuehn BM. Despite curbing new drug shortages, shortfall of drugs a persistent problem. JAMA. 2013;309(6):532-533.
9. Borchardt RA, Rolston KV. Antibiotic shortages: effective alternatives in the face of a growing problem. JAAPA. 2013;26(2):13-18.
10. Kweder SL, Dill S. Drug shortages: the cycle of quantity and quality. Clin Pharmacol Ther. 2013;93(3):245-251.
11. Mirtallo JM, Holcombe B, Kochevar M, Guenter P. Parenteral nutrition product shortages: the A.S.P.E.N. strategy. Nutr Clin Pract. 2012;27(3):385-391.
12. Havrilesky LJ, Garfield CF, Barnett JC, Cohn DE. Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer. Gynecol Oncol. 2012;125(3):631-634.
13. Chabner BA. Drug shortages - a critical challenge for the generic-drug market. N Engl J Med. 2011;365(23):2147-2149.
14. European Medicines Agency. Reflection Paper on Medicinal Product Supply Shortages Caused by Manufacturing/good manufacturing practice compliance Problems. London: European Medicines Agency; 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/11/WC500135113.pdf. Accessed September 15, 2014.
15. Huys I, Simoens S. European drug shortages: a call for action! Int J Pharm Pract. 2013;21(1):1-2.
16. García Rada A. "A generation of cancer patients is being sacrificed" because of drug shortages in Europe, expert says. BMJ. 2012;344:e4411.
17. Canadian Pharmacists Association [webpage on the Internet]. Canadians paying the price for drug shortages: survey. Available from: www.pharmacists.ca/index.cfm/news-events/news/canadians-paying-the-price-for-drug-shortages-survey/. Accessed September 15, 2014.
18. Health Canada [webpage on the Internet]. Drug shortages protocol and toolkit. Available from: http://www.hc-sc.gc.ca/ahc-asc/media/nr-cp/_2013/2013-125fs-eng.php. Accessed September 15, 2014.
19. International Society for Pharmaceutical Engineering [webpage on the Internet]. Report on the ISPE drug shortages survey. Available from: http://www.ispe.org/drug-shortages-initiative. Accessed September 15, 2014.
20. Fox ER, Birt A, James KB, Kokko H, Salverson S, Soflin DL; ASHP Expert Panel on Drug Product Shortages. ASHP guidelines on managing drug product shortages in hospitals and health systems. Am J Health Syst Pharm. 2009;66(15):1399-1406.
21. Institute for Safe Medication Practices. Drug shortages: national survey reveals high level of frustration, low level of safety. Acute Care. 2010;15(15):1-6.
22. Becker DJ, Talwar S, Levy BP, et al. Impact of oncology drug shortages on patient therapy: unplanned treatment changes. J Oncol Pract. 2013;9(4):e122-e128.
23. McBride A, Holle LM, Westendorf C, et al. National survey on the effect of oncology drug shortages on cancer care. Am J Health Syst Pharm. 2013;70(7):609-617.
24. Kaakeh R, Sweet BV, Reilly C, et al. Impact of drug shortages on U.S. health systems. Am J Health Syst Pharm. 2011;68(19):1811-1819.
25. Institute for Safe Medication Practices. A shortage of everything except errors: harm associated with drug shortages. Acute Care. 2012;17:1-4.
26. Goldsack JC, Reilly C, Bush C, et al. Impact of shortages of injectable oncology drugs on patient care. Am J Health Syst Pharm. 2014;71(7):571-578.
27. Goozner M. Drug shortages delay cancer clinical trials. J Natl Cancer Inst. 2012;104(12):891-892.
28. Kaiser J. Medicine. Shortages of cancer drugs put patients, trials at risk. Science. 2011;332(6029):523.
29. Manolakis M. Ethical integrity in managing drug shortages. Am J Health Syst Pharm. 2012;69(1):17.
30. Valgus J, Singer EA, Berry SR, Rathmell WK. Ethical challenges: managing oncology drug shortages. J Oncol Pract. 2013;9(2):e21-e23.
31. Jagsi R, Spence R, Rathmell WK, et al. Ethical considerations for the clinical oncologist in an era of oncology drug shortages. Oncologist. 2014;19(2):186-192.
32. Lipworth W, Kerridge I. Why drug shortages are an ethical issue. Australas Med J. 2013;6(11):556-559.
33. US Senate, Committee on Health Education Labor and Pensions. Building a 21st Century FDA: Proposals to Improve Drug Safety and Innovation. Senate Hearing 109-850. Washington, DC: US Government Printing Office; 2007.
34. US Food and Drug Administration. Washington, DC: US Food and Drug Administration; 2013. Strategic Plan for Preventing and Mitigating Drug Shortages. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/DrugShortages/UCM372566.pdf. Accessed September 15, 2014.
35. US Food and Drug Administration. SOPP 8506: Management of Shortages of CBER-regulated Products. Washington, DC: US Food and Drug Administration; 2012. Available from: http://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/proceduressopps/ucm299324.pdf. Accessed September 15, 2014.
36. US Food and Drug Administration. Washington, DC: US Food and Drug Administration. MAPP 6003.1: Office of New Drugs. Drug Shortage Management. Available from: http://www.fda.gov/downloads/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/manualofpoliciesprocedures/ucm079936.pdf. Accessed September 15, 2014.
37. American Society of Clinical Oncology [webpage on the Internet]. Comments on the government accountability office report on drug shortages. Available from: http://www.asco.org/advocacy/asco-comments-gao-report-drug-shortages. Accessed September 15, 2014.
38. American Society of Clinical Oncology [webpage on the Internet]. ASCO, NCCR support FDA proposed rule on drug manufacturing interruptions. Available from: http://www.asco.org/advocacy/asco-nccr-support-fda-proposed-rule-drug-manufacturing-interruptions. Accessed September 15, 2014.
39. Rider AE, Templet DJ, Daley MJ, Shuman C, Smith LV. Clinical dilemmas and a review of strategies to manage drug shortages. J Pharm Pract. 2013;26(3):183-191.
40. Johnson PE. Drug shortages: impact and strategies. J Natl Compr Canc Netw. 2011;9(8):815-819.
41. Decamp M, Joffe S, Fernandez CV, Faden RR, Unguru Y; Working Group on Chemotherapy Drug Shortages in Pediatric Oncology. Chemotherapy drug shortages in pediatric oncology: a consensus statement. Pediatrics. 2014;133(3):e716-e724.
42. United States House of Representatives. Washington, DC: United States House of Representatives. Public Health Service Act. Available from: http://www.house.gov/legcoun/Comps/PHSA_CMD.pdf. Accessed September 15, 2014.
43. US Food and Drug Administration. Washington, DC: US Food and Drug Administration; 2009. Biologics Price Competition and Innovation Act, 2009. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/UCM216146.pdf. Accessed September 15, 2014.
44. US Food and Drug Administration. Draft guidance for industry on scientific considerations in demonstrating biosimilarity to a reference product. Available from: http://www.fda.gov. Accessed September 15, 2014.
45. US Food and Drug Administration. Draft guidance for industry on quality considerations in demonstrating biosimilarity to a reference protein product. Available from: http://www.fda.gov. Accessed September 15, 2014.
46. European Medicines Agency. London: European Medicines Agency; 2012. Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies-Non-clinical and Clinical Issues. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf. Accessed September 15, 2014.
47. European Medicines Agency. London: European Medicines Agency; 2012. Guideline on Immunogenicity Assessment of Monoclonal Antibodies Intended for In Vivo Clinical Use. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128688.pdf. Accessed September 15, 2014.
48. Zelenetz AD, Ahmed I, Braud EL, et al. NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw. 2011;9(Suppl 4):S1-S22.
49. Akbarzadeh-Sharbaf S, Yakhchali B, Minuchehr Z, Shokrgozar MA, Zeinali S. In silico design, construction and cloning of Trastuzumab humanized monoclonal antibody: a possible biosimilar for Herceptin. Adv Biomed Res. 2012;1:21.
50. Yin D, Barker KB, Li R, et al. A randomised phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327-01). Br J Clin Pharmacol. 2014;78(6):1281-1290.
51. Hurst S, Ryan AM, Ng CK, et al. Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin(®)). Bio Drugs. 2014;28(5):451-459.
52. Im Y-H, Odarchenko P, Grecea D, et al. Double-blind, randomized, parallel group, phase III study to demonstrate equivalent efficacy and comparable safety of CT-P6 and trastuzumab, both in combination with paclitaxel, in patients with metastatic breast cancer (MBC) as first-line treatment. J Clin Oncol. 2013;31(Suppl):Abstract 629.
53. Stenina MB, Ignatova E, Frolova MA, et al. Pharmacokinetics and safety of BCD-022, trastuzumab biosimilar candidate, compared to Herceptin in patients. J Clin Oncol. 2014;32(Suppl):Abstract e11576.
54. Ryan AM, Sokolowski SA, Ng CK, et al. Comparative nonclinical assessments of the proposed biosimilar PF-05280586 and rituximab (MabThera®). Toxicol Pathol. 2014;42(7):1069-1081.
55. Yin D, Becker J-C, Melia L, et al. A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in subjects with active rheumatoid arthritis (REFLECTIONS B328-01). Ann Rheum Dis. 2014;73(Suppl 2):497.
56. Visser J, Feuerstein I, Stangler T, Schmiederer T, Fritsch C, Schiestl M. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. Bio Drugs. 2013;27(5):495-507.
57. Poddubnaya I, Babicheva L, Kaplanov K, et al. Comparison of pharmacokinetics and pharmacodynamics of BCD-020 with innovator rituximab in patients with indolent non-Hodgkin lymphoma. J Clin Oncol. 2014;32(Suppl):Abstract e19545.
58. Seigelchifer M, Corley E, Fresnillo G, et al. Development of RTXM83 (a potential rituximab biosimilar): in vitro and in vivo comparability with MabThera. J Clin Oncol. 2014;32(Suppl):Abstract e14020.
59. Orlov S, Burdaeva O, Nechaeva M, et al. Pharmacokinetics and safety of BCD-021, a bevacizumab biosimilar candidate, compared to Avastin in patients. J Clin Oncol. 2014;32(Suppl):Abstract e13500.
60. Mica A, Mutomba M, Green L. Steps to ensure adequate supply of biological medicines: considerations for the healthcare provider. GaBI J. 2013;2(3):136-143.
61. Generics and Biosimilar Initiative News [webpage on the Internet]. Biosimilars and cancer drug shortages in Europe. Available from: http://gabionline.net/Pharma-News/Biosimilars-and-cancer-drug-shortages-in-Europe. Accessed September 15, 2014.
62. Weise M, Bielsky M, De Smet K, et al. Biosimilars - why terminology matters. Nat Biotechnol. 2011;29(8):690-693.
63. Lucio SD, Stevenson JG, Hoffman JM. Biosimilars: Implications for health system pharmacists. Am J Health Syst Pharm. 2013;70(22):2004-2017.
64. Hospira UK Limited. Inflectra (infliximab) European Public Assessment Report Summary of Product Characteristics. Warwickshire, UK: Hospira UK Limited; 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002778/WC500151489.pdf. Accessed September 15, 2014.
65. Celltrion Healthcare Hungary Kft. Remsima (infliximab) European Public Assessment Report Summary of Product Characteristics. Budapest, Hungary: Celltrion Healthcare Hungary Kft; 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002576/WC500150871.pdf. Accessed September 15, 2014.